The Journal of Nuclear Medicine ahead-of-print tip sheet: February 27, 2026
Peer-Reviewed Publication
Updates every hour. Last Updated: 25-Jun-2026 10:16 ET (25-Jun-2026 14:16 GMT/UTC)
A team from the Monash University Biomedicine Discovery Institute in Australia has identified a tick-derived evasin that can bind to two major classes of chemokines, a discovery that is important for the development of therapeutics targeting inflammatory and autoimmune diseases. Until now, scientists had identified only evasins that selectively block chemokines within a single class.
Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness
The therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens and help support the World Health Organization’s (WHO) goal of eliminating the disease by 2030
Sanofi will donate the medicine to WHO through its philanthropic arm Foundation S
Reduced international donor funding associated with higher household economic burden of Tuberculosis in low- and middle-income countries, according to modelling stud